ANJESO Drug Patent Profile

Which patents cover Anjeso, and what generic alternatives are available?

Anjeso is a drug marketed by Baudax and is included in one NDA. There are five patents protecting this drug.

This drug has forty-seven patent family members in thirteen countries.

The generic ingredient in ANJESO is meloxicam. There are twenty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Anjeso

A generic version of ANJESO was approved as meloxicam by AVONDALE PHARMS on June 1^st, 2004.

Summary for ANJESO

International Patents:	47
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	145
Clinical Trials:	1
Drug Prices:	Drug price information for ANJESO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ANJESO
What excipients (inactive ingredients) are in ANJESO?	ANJESO excipients list
DailyMed Link:	ANJESO at DailyMed

See drug prices for ANJESO

Recent Clinical Trials for ANJESO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yangtze River Pharmaceutical Group Co., Ltd.	PHASE1

See all ANJESO clinical trials

US Patents and Regulatory Information for ANJESO

ANJESO is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No	10,709,713
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No	11,253,478		Y
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No	11,458,145
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No	10,881,663
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No	9,974,746		Y

Expired US Patents for ANJESO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020	10,463,673
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020	10,471,067
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020	8,512,727

EU/EMA Drug Approvals for ANJESO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Norbrook Laboratories (Ireland) Limited	Loxicom	meloxicam	EMEA/V/C/000141DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2009-02-10
Le Vet Beheer B.V.	Novaquin	meloxicam	EMEA/V/C/003866Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.	Authorised	no	no	no	2015-09-08
Le Vet Beheer B.V	Meloxidolor	meloxicam	EMEA/V/C/002590DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2013-04-22
Boehringer Ingelheim Vetmedica GmbH	Novem	meloxicam	EMEA/V/C/000086Novem 5-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.Novem 20-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Novem 40 mg/ml solution for injection for cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.	Authorised	no	no	no	2004-03-02
Boehringer Ingelheim Vetmedica GmbH	Metacam	meloxicam	EMEA/V/C/000033Cats:Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of post-operative pain following dehorning in calves.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.Dogs:Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Horses:For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.For the relief of pain associated with equine colic.Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of post-operative pain associated with minor soft tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Guinea pigs:Alleviation of mild to moderate post-operative pain associated with soft tissues surgery such as male castration.	Authorised	no	no	no	1998-01-07
Chanelle Pharmaceuticals Manufacturing Limited	Rheumocam	meloxicam	EMEA/V/C/000121DogsAlleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. To reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.CatsReduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy. For the relief of post operative pain associated with minor soft tissue such as castration.HorsesAlleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses..For the relief of pain associated with equine colic.	Authorised	yes	no	no	2008-01-10
Emdoka bvba	Emdocam	meloxicam	EMEA/V/C/002283CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitits-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. For the relief of pain associated with equine colic.Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Cats:Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.	Authorised	yes	no	no	2011-08-18

International Patents for ANJESO

See the table below for patents covering ANJESO around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	201043264	Reduction of flake-like aggregation in nanoparticulate active agent compositions
Japan	4891774
Japan	2012012397	NANOPARTICULATE MELOXICAM FORMULATION
Canada	2763456
Japan	2011042670	NANOPARTICULATE MELOXICAM FORMULATION
Japan	6694682
Japan	2007505154

Market Dynamics and Financial Trajectory for Anjeso: An In-Depth Analysis

Last updated: July 27, 2025

Introduction

Anjeso, the brand name for the novel injectable NSAID, has garnered considerable attention within the pharmaceutical landscape owing to its unique formulation and targeted clinical applications. As a recently approved agent for managing moderate to severe pain, particularly in the oncology and postoperative settings, Anjeso's market entry signifies a potential shift in analgesic therapy. This analysis explores the intricate market dynamics and forecasted financial trajectory of Anjeso, considering factors from regulatory approvals to competitive landscape, pricing strategies, and evolving healthcare practices.

Regulatory Milestones and Market Authorization

Anjeso received FDA approval in early 2022, underlining its safety and efficacy profile substantiated by pivotal clinical trials demonstrating significant pain relief with a favorable safety margin. This regulatory green light has propelled Anjeso into the US market, with subsequent submissions underway in Europe and other major territories. The approval has particular relevance in the context of opioid-sparing approaches, emphasizing its role in multimodal pain management protocols.

Target Indications and Clinical Positioning

Anjeso's primary indications include managing moderate to severe pain in oncology patients and postoperative environments, especially where NSAID use is advantageous over opioids due to safety concerns. Its rapid onset and sustained action position it as a valuable alternative for healthcare providers seeking opioid-sparing strategies, driven by ongoing opioid crisis concerns and regulatory pressures to minimize opioid prescriptions.

Market Landscape and Competitive Environment

The analgesic market segment targeted by Anjeso is highly competitive, dominated by established NSAIDs such as ketorolac, diclofenac, and other injectable formulations. However, Anjeso’s distinct pharmacokinetic profile, with increased bioavailability and reduced gastrointestinal toxicity, offers a strategic advantage.

Key competitors include traditional NSAIDs and emerging agents such as self-administered pain management devices and novel local anesthetics. Additionally, the broader opioid alternatives landscape includes medications like morphine and fentanyl, but these face increasing scrutiny due to addiction risks.

Market Drivers

Several drivers underpin Anjeso’s market expansion:

• Shift Towards Opioid Alternatives: Hospitals and clinicians prioritize non-opioid pain relief due to addiction concerns, regulatory restrictions, and the opioid epidemic.
• Enhanced Pain Management Protocols: Growing adherence to multimodal analgesia protocols incorporating NSAIDs improves Anjeso’s utilization prospects.
• Pediatric and Oncology Applications: Anjeso’s safety profile suits vulnerable populations, expanding its potential use cases.
• Healthcare System Policies: Increased focus on reducing opioid prescriptions and promoting non-opioid analgesics in surgical pathways.

Market Barriers and Challenges

Despite promising prospects, Anjeso faces several barriers:

• Pricing and Reimbursement: Positioned as a premium product, reimbursement negotiations with payers, especially in consolidated healthcare markets, will influence uptake.
• Competition from Established NSAIDs: Conventional NSAID formulations and emerging products might pressure pricing and usage.
• Clinical Adoption: Slow clinician acceptance due to familiarity with existing agents or hesitancy regarding novel formulations requires targeted education.
• Regulatory Approvals in Key Markets: Delays or denials outside the US could constrain international growth.

Financial Trajectory and Revenue Forecasts

Projections suggest a cautious but optimistic path for Anjeso’s revenue growth, contingent on adoption rates, pipeline developments, and market penetration. Based on initial launch data and clinical utility estimates:

• Short-term (1-2 years): Revenue primarily driven by initial adoption in major US hospital systems; expected to reach $100 million in Year 1, with a growth rate of approximately 30% in Year 2. The focus remains on targeted indications such as postoperative pain in major surgical centers and oncology inpatient settings.

• Mid-term (3-5 years): Expansion into ambulatory surgery centers and outpatient pain clinics, along with increased acceptance in Europe and Asia post regulatory approvals. Forecasted revenues could surpass $300 million, with compound annual growth rates (CAGR) of around 25-30%.

• Long-term (5+ years): Market penetration stabilizes with possible pipeline additions—such as novel formulations or combination therapies—potentially pushing revenues beyond $500 million globally. The integration of Anjeso into bundled pain management protocols and hospital formularies remains a crucial growth lever.

Price Point and Market Penetration Strategies

Anjeso’s pricing is aligned with premium NSAID products, approximately $100-$150 per dose, reflecting its novel delivery mechanism and clinical benefits. Reimbursement strategies focus on demonstrating cost-effectiveness through reduced opioid-related side effects and shorter hospital stays. Value-based pricing models, coupled with clinical data showcasing improved patient outcomes, are vital for market acceptance.

Impact of Healthcare Trends

Evolving healthcare practices toward minimizing opioid dependence influence Anjeso’s trajectory positively. Hospitals aim to meet regulatory standards and patient safety benchmarks, assigning higher priority to NSAID-based pain management options. Digital health integrations and clinical decision support tools further facilitate adoption.

Conclusion

Anjeso’s market dynamics are characterized by strategic positioning within a competitive analgesic landscape, driven by prevailing healthcare policies and clinical needs. Its financial trajectory, anchored in initial cautious adoption and subsequent broader acceptance, projects a promising upward trend. Navigating reimbursement hurdles, fostering clinician awareness, and capturing international markets will be central to realizing its growth potential.

---

Key Takeaways

• Strategic Positioning: Anjeso’s unique formulation and safety profile solidify its role as an opioid-sparing analgesic, aligning with current healthcare priorities.
• Market Expansion: Significant opportunities exist in surgical, oncology, and outpatient pain management, with potential growth in international markets.
• Revenue Forecasts: Expected to reach $300 million globally within 3-5 years, contingent on market acceptance and reimbursement strategies.
• Pricing and Reimbursement: Premium pricing requires demonstrable cost-effectiveness; partnerships with payers likely critical.
• Market Challenges: Competition from established NSAIDs and slow clinician adoption remain hurdles; proactive education and evidence dissemination are essential.

---

FAQs

1. What distinguishes Anjeso from traditional NSAID formulations?
Anjeso’s novel injectable formulation offers rapid onset and longer duration of pain relief with a favorable safety profile, particularly reduced gastrointestinal toxicity, making it suitable for acute pain management in vulnerable populations.

2. How does Anjeso fit within current opioid-sparing pain management protocols?
Anjeso serves as an effective non-opioid analgesic option, aligning with multimodal pain management strategies that aim to reduce opioid use due to addiction risks and regulatory scrutiny.

3. What are the primary markets for Anjeso’s expansion?
Initial focus centers on the US hospital system, particularly surgical and oncology settings. Future growth prospects include Europe, Asia, and outpatient clinics, assuming regulatory approvals.

4. How might reimbursement policies affect Anjeso’s market penetration?
Reimbursement negotiations will be pivotal. Demonstrating cost savings related to shorter hospital stays and reduced opioid dependency will strengthen market acceptance.

5. What are potential future developments for Anjeso?
Pipeline opportunities include combining Anjeso with other analgesics, developing formulations for specific patient populations, and expanding into chronic pain indications, broadening its therapeutic scope.

---

References

[1] FDA Approval Announcement for Anjeso, 2022.
[2] Industry Reports on NSAID Market Dynamics, 2023.
[3] Clinical Trial Data on NSAID Efficacy and Safety, 2022.
[4] Healthcare Policy Analyses on Opioid Reduction Strategies, 2022.
[5] Market Forecast Reports by Pharmaceutical Intelligence, 2023.